Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 30, 2026 → Jun 30, 2027
See other at-risk trials from Mount Sinai Hospital, Canada

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 30, 2026 to Jun 30, 2027 Show 5 more changesShow less
    • Study completion pushed from Mar 31, 2027 to Mar 31, 2028
    • Study sites: 23 to 22
    • Secondary endpoints: details revised at 2 of 6 entries
    • Collaborators: 24 to 21
    • Eligibility criteria expanded, about 4 words
  2. Minor Study sites: 26 to 23
    • Collaborators: 27 to 24
    v11
  3. Minor Site contacts updated at 1 of 26 sites
    • Collaborators: 26 to 27
    v10
  4. Minor Study sites: 27 to 26
    • Collaborators: 27 to 26
    v9
  5. Minor Study sites: 26 to 27
    • Collaborators: 26 to 27
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 20 to 26
    • Collaborators: 21 to 26
    v7
  2. Minor Site details revised at 3 of 20 sites
    • Collaborators: 14 to 21
    v6
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 15 to 20
    • Start date changed from estimate of Feb 2023 to Feb 6, 2023
    v5
  4. Notable Start date: Nov 2022 to Feb 2023v4
  5. Notable Start date: Sep 2022 to Nov 2022v3
  6. Notable Start date: Jul 1, 2022 to Sep 2022v2
  1. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices. Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS. Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS. Hypothesis: Primary treatment with NE will be associated with a lower mortality Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved: Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Trial Details
NCT Number NCT05347238
Lead Sponsor Mount Sinai Hospital, Canada
Collaborators: Sunnybrook Health Sciences Centre, The Hospital for Sick Children, London Health Sciences Centre, Windsor Regional Hospital, Foothills Medical Centre, Health Sciences Centre, Winnipeg, Manitoba, St. Boniface Hospital, Jewish General Hospital, St. Justine's Hospital, IWK Health Centre, University College Cork, Island Health, Victoria, BC, Assaf-Harofeh Medical Center, Dayton Children's Hospital, Banner University Medical Center, Methodist Healthcare - Memphis, Hospital Universitario La Paz, McMaster Children's Hospital, Children's Hospital of Eastern Ontario, BC Women's Hospital & Health Centre, Stony Brook University
Conditions
(from sponsor)
Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension
Related terms Neonatal Sepsis
Enrollment 550 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov